Optic

Abstract

Tislelizumab combined with nab-paclitaxel single-agent chemotherapy plus bevacizumab for patients with EGFR-TKIs-resistant advanced NSCLC with ECOG PS 0-2.

Org: National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital, Guangzhou Medical University, Department of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health,

Abstract

Flushing fluid of post-bronchoscopic biopsy as a novel liquid biopsy specimen for genome profiling in advanced lung cancer.

Org: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, Guangzhou Institute of Respiratory Health, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University,

Abstract

Safety and preliminary efficacy of YK-029A, a novel EGFR TKI, in patients with advanced NSCLC harboring ex20ins, T790M or rare mutations.

Org: State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,

Abstract

A multicenter phase I/II trial of induction chemotherapy followed by camrelizumab, apatinib, plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer.

Org: Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, Guangzhou Institute of Respiratory Health, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University,